智翔金泰：赛立奇单抗注射液被纳入2025年国家医保目录

Core Viewpoint - Zhixiang Jintai's self-developed drug, Saliqi monoclonal antibody injection (Jinlixi), has been successfully included in the National Medical Insurance Directory for 2025, which will take effect on January 1, 2026 [1] Company Summary - Zhixiang Jintai (688443) announced the inclusion of its drug in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory [1]